GSK Buys Experimental Multiple Myeloma Drug from Chimagen
GSK will buy a Chimagen trispecific T-cell engager for multiple myeloma. Phase I trials start in 2027. The deal is worth up to $750 million.
/ 23 items
#GSK↓
GSK posts strong lung cancer data at WCLC as it seeks first-line Jideytro approval
Jideytro shrank tumors in 94% of untreated ROS1 patients; Ris-Rez cut death risk 54% vs topotecan in China. FDA filing planned this year.
HUTCHMED and GSK Sign Deal for Dual-Targeted KRAS-EGFR Cancer Drug
HUTCHMED licenses HMPL-A830, a KRAS-EGFR ATTC, to GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers.
GSK Discontinues Camlipixant After Mixed Phase 3 Results in Chronic Cough
The company will continue developing the drug for irritable bowel syndrome (IBS).
No Efficacy or Safety Issues: Achieve Life Sciences Gets FDA CRL for Cytisinicline
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.
GSK Buys Nuvalent for $10.6 Billion in Massive Cancer Drug Bet
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.